Equities Analysts Issue Forecasts for RNTX FY2030 Earnings

Rein Therapeutics Inc. (NASDAQ:RNTX) – HC Wainwright lifted their FY2030 earnings estimates for Rein Therapeutics in a report issued on Monday, June 1st. HC Wainwright analyst B. Folkes now forecasts that the company will earn $0.55 per share for the year, up from their previous estimate of $0.43. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Rein Therapeutics’ current full-year earnings is ($1.63) per share.

Separately, Wall Street Zen raised shares of Rein Therapeutics to a “sell” rating in a research report on Saturday, May 16th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Rein Therapeutics presently has a consensus rating of “Hold” and an average target price of $7.00.

Rein Therapeutics Stock Performance

Shares of RNTX opened at $1.07 on Tuesday. The stock has a market capitalization of $91.53 million, a PE ratio of -0.56 and a beta of 1.35. Rein Therapeutics has a 1 year low of $0.95 and a 1 year high of $2.18. The company’s 50-day simple moving average is $1.32 and its 200-day simple moving average is $1.30.

Rein Therapeutics (NASDAQ:RNTX) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.30.

Institutional Trading of Rein Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Voss Capital LP raised its holdings in Rein Therapeutics by 59.2% during the fourth quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock worth $4,923,000 after purchasing an additional 1,577,437 shares in the last quarter. Vanguard Group Inc. raised its holdings in Rein Therapeutics by 32.2% during the third quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after purchasing an additional 284,300 shares in the last quarter. Prosight Management LP raised its holdings in Rein Therapeutics by 32.7% during the third quarter. Prosight Management LP now owns 567,898 shares of the company’s stock worth $650,000 after purchasing an additional 139,979 shares in the last quarter. Cable Car Capital LP acquired a new stake in Rein Therapeutics during the second quarter worth approximately $588,000. Finally, Sigma Planning Corp raised its holdings in Rein Therapeutics by 41.0% during the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after purchasing an additional 101,400 shares in the last quarter. Institutional investors and hedge funds own 90.89% of the company’s stock.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.